Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis

Pediatr Res. 2016 Feb;79(2):295-300. doi: 10.1038/pr.2015.215. Epub 2015 Oct 22.

Abstract

Background: Diabetic ketoacidosis (DKA) in children is associated with cerebrovascular-related complications. We recently reported that DKA facilitates leukocyte adherence to the brain microvascular endothelium. Adhered leukocytes can release enzymes that instigate vascular dysfunction. Our aims were to measure plasma levels of leukocyte-derived matrix metalloproteinases (MMPs) from DKA patients and to correlate plasma MMP concentrations with DKA severity.

Methods: Plasma was obtained from children with type 1 diabetes, either in DKA (n = 16) or insulin controlled (CON; n = 16). Antibody microarray and gelatin zymography were used to quantify plasma MMPs and their endogenous tissue inhibitors (TIMPs). MMP concentrations were correlated with DKA severity (blood pH). Quantitative PCR of leukocyte mRNA was used to help determine the origin of plasma MMPs.

Results: DKA was associated with altered plasma levels of ↓MMP-2 (P < 0.001), ↑MMP-8 (P < 0.001), ↑MMP-9 (P < 0.05), and ↑TIMP-4 (P < 0.001), as compared with CON. Elevated MMP-8 and MMP-9 were both positively correlated with DKA severity (P < 0.05). DKA was associated with increased leukocyte mRNA for MMP-8, MMP-9, and TIMP-4 (P < 0.005).

Conclusion: MMPs are dynamically regulated during DKA. Plasma MMP-8 and MMP-9 concentrations correlate with DKA severity and are known to degrade brain microvascular endothelial cell tight junctions. Thus, leukocyte-derived MMPs might contribute to DKA-associated cerebrovascular complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Child
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetic Ketoacidosis / blood
  • Diabetic Ketoacidosis / enzymology*
  • Diabetic Ketoacidosis / etiology
  • Female
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Leukocytes / enzymology*
  • Male
  • Matrix Metalloproteinase 2 / blood
  • Matrix Metalloproteinase 8 / blood*
  • Matrix Metalloproteinase 8 / genetics
  • Matrix Metalloproteinase 9 / blood*
  • Matrix Metalloproteinase 9 / genetics
  • RNA, Messenger / blood
  • Severity of Illness Index
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-4
  • Tissue Inhibitor of Metalloproteinases / blood

Substances

  • Biomarkers
  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinases
  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • MMP8 protein, human
  • Matrix Metalloproteinase 8
  • MMP9 protein, human
  • Matrix Metalloproteinase 9